MS4A3 Promotes the Chemosensitivity of Lung Cancer via THAP1/EGFR Pathways

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• MS4A3 is recognized as a tumor suppressor in various cancers, but its role in lung cancer remains uncharacterized.
• Understanding MS4A3's function is crucial for developing novel therapeutic strategies for lung cancer.

Purpose of the Study:

• To investigate the role and potential of MS4A3 in non-small-cell lung cancer (NSCLC).
• To elucidate the molecular mechanisms underlying MS4A3's function in lung cancer, including its interaction with THAP1 and EGFR.

Main Methods:

• Quantitative reverse transcription polymerase chain reaction (RT-qPCR) for gene expression analysis.
• Cell proliferation assays (CCK-8, colony formation), apoptosis assays (flow cytometry), and angiogenesis assays (tube formation).
• Chromatin immunoprecipitation (ChIP) and luciferase assays to confirm molecular interactions and transcriptional regulation.

Main Results:

• MS4A3 expression is significantly downregulated in NSCLC patients, correlating with poor clinical outcomes.
• Overexpression of MS4A3 increases NSCLC cell sensitivity to osimertinib, while knockdown reduces it.
• MS4A3 suppresses tumor proliferation and angiogenesis, and promotes apoptosis by upregulating THAP1, which transcriptionally inactivates EGFR.

Conclusions:

• MS4A3 functions as a potent anti-tumor gene in NSCLC.
• The MS4A3/THAP1/EGFR signaling pathway is a key regulator of lung cancer progression and chemosensitivity to EGFR tyrosine kinase inhibitors (TKIs).